Results 11 to 20 of about 61,613 (221)
Acta Pharmaceutica Sinica B, 2023 Irinotecan is an anticancer topoisomerase I inhibitor that acts as a prodrug of the active metabolite, SN-38. Unfortunately, the limited utility of irinotecan is attributed to its pH-dependent stability, short half-life and dose-limiting toxicity.
Shiwen Song +9 more
doaj +2 more sources
Irinotecan Pharmacogenomics [PDF]
Pharmacogenomics, 2010 Irinotecan is a camptothecin analog used as an anticancer drug. Severe, potentially life-threatening toxicities can occur from irinotecan treatment. Although multiple genes may play a role in irinotecan activity, the majority of evidence to date suggests that variation in expression of UGT1A1 caused by a common promoter polymorphism (UGT1A1*28) is ...
Sharon, Marsh, Janelle M, Hoskins
openaire +4 more sources
Irinotecan-Induced Dysarthria [PDF]
Case Reports in Oncology, 2012 Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease. Here, we describe the case of a 46-year-old patient with metastatic rectal carcinoma who received second-line therapy with irinotecan and developed isolated transient dysarthria (with normal MR imaging of the
Dressel, A.J. +4 more
openaire +5 more sources
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity [PDF]
BMC Microbiology, 2023 Background Irinotecan is a chemotherapeutic agent used to treat a variety of tumors, including colorectal cancer (CRC). In the intestine, it is transformed into SN-38 by gut microbial enzymes, which is responsible for its toxicity during excretion ...
Marwa S. Mahdy +7 more
doaj +2 more sources
PLoS ONE, 2015 Irinotecan, an analogue of camptothecin, is frequently used as a single agent or in combination with other anticancer drugs for the treatment of colorectal cancer. However, the drug resistance of tumors is a major obstacle to successful cancer treatment.
Seung Ho Choi +4 more
doaj +2 more sources
Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report [PDF]
Case Reports in Oncology, 2021 Irinotecan hydrochloride (irinotecan) is a chemotherapeutic agent used in the treatment of solid tumors. In addition to severe neutropenia and delayed diarrhea, irinotecan causes cholinergic syndrome, characterized by abdominal pain and acute diarrhea ...
Kazuki Uchiyama +4 more
doaj +2 more sources
BMC Gastroenterology, 2018 Background For patients with advanced gastric cancer (AGC), second-line chemotherapy regimen remains controversial. The efficacy and safety of irinotecan-containing doublet treatment and irinotecan monotherapy were compared in this systematic analysis ...
Liuting Yang +7 more
doaj +2 more sources
Protective role of Lactobacillus plantarum A7 against irinotecan-induced genotoxicity [PDF]
Avicenna Journal of Phytomedicine, 2016 Objective: Irinotecan is a botanical derivative and an anti-cancer drug with cytotoxic and genotoxic effects. The present study evaluated the effect of Lactobacillus plantarum A7 on the genotoxic activity of irinotecan in a hepatocellular carcinoma cell ...
Soheila Sepahi +4 more
doaj +1 more source
Cancer Medicine, 2023 Background Subgroup analyses of the NAPOLI‐1 study identified that among patients who were irinotecan naïve prior to entering the clinical trial, a survival benefit was observed between the study arm and control arm.
Kenneth H. Yu +5 more
doaj +2 more sources
Pharmaceuticals, 2020 Irinotecan, an anticancer drug, induces diarrhea and intestinal inflammation, resulting in an increase in the cost of care and in treatment delays.
Daniely V. S. Costa +12 more
doaj +2 more sources